ALNYLAM PHARMACEUTICALS, INC. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$134.81 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-04.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2018-05-04
- ALNYLAM PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-03-31 was -$134.81M, a 279.57% decline year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-12-31 was -$160.59M, a 259.96% decline year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-09-30 was -$137.18M.
- ALNYLAM PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was -$67.67M.
- ALNYLAM PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was -$290.36M, a 303.63% decline from fiscal 2016.
- ALNYLAM PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was $142.59M.
- ALNYLAM PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$321.32M.
- ALNYLAM PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$548.81M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2018-03-31 | -$134.81M 10-Q · filed 2018-05-04 | -$295.40M derived: sum of 2 quarters · filed 2018-05-04 | -$432.58M derived: sum of 3 quarters · filed 2018-05-04 | -$500.25M derived: sum of 4 quarters · filed 2018-05-04 |
| 2017-12-31 | -$160.59M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | -$297.77M derived: sum of 2 quarters · filed 2018-02-15 | -$365.44M derived: sum of 3 quarters · filed 2018-02-15 | -$290.36M 10-K · filed 2018-02-15 |
| 2017-09-30 | -$137.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$204.85M derived: sum of 2 quarters · filed 2017-11-07 | -$129.77M 10-Q · filed 2017-11-07 | -$29.38M derived: sum of 4 quarters · filed 2018-05-04 |
| 2017-06-30 | -$67.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $7.41M 10-Q · filed 2017-08-09 | $107.80M derived: sum of 3 quarters · filed 2018-05-04 | $76.39M derived: sum of 4 quarters · filed 2018-05-04 |
| 2017-03-31 | $75.08M 10-Q · filed 2018-05-04 | $175.47M derived: sum of 2 quarters · filed 2018-05-04 | $144.06M derived: sum of 3 quarters · filed 2018-05-04 | $99.73M derived: sum of 4 quarters · filed 2018-05-04 |
| 2016-12-31 | $100.39M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $68.99M derived: sum of 2 quarters · filed 2018-02-15 | $24.65M derived: sum of 3 quarters · filed 2018-02-15 | $142.59M 10-K · filed 2018-02-15 |
| 2016-09-30 | -$31.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$75.74M derived: sum of 2 quarters · filed 2017-11-07 | $42.20M 10-Q · filed 2017-11-07 | $120.47M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-06-30 | -$44.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $73.61M 10-Q · filed 2017-08-09 | $151.88M derived: sum of 3 quarters · filed 2018-02-15 | $200.55M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-03-31 | $117.94M 10-Q · filed 2017-05-05 | $196.21M derived: sum of 2 quarters · filed 2018-02-15 | $244.88M derived: sum of 3 quarters · filed 2018-02-15 | $137.95M derived: sum of 4 quarters · filed 2018-02-15 |
| 2015-12-31 | $78.27M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $126.94M derived: sum of 2 quarters · filed 2018-02-15 | $20.01M derived: sum of 3 quarters · filed 2018-02-15 | -$321.32M 10-K · filed 2018-02-15 |
| 2015-09-30 | $48.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | -$58.27M derived: sum of 2 quarters · filed 2016-11-03 | -$399.59M 10-Q · filed 2016-11-03 | -$378.16M derived: sum of 4 quarters · filed 2017-02-15 |
| 2015-06-30 | -$106.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | -$448.26M 10-Q · filed 2016-08-04 | -$426.83M derived: sum of 3 quarters · filed 2017-02-15 | -$388.92M derived: sum of 4 quarters · filed 2017-02-15 |
| 2015-03-31 | -$341.33M 10-Q · filed 2016-05-04 | -$319.89M derived: sum of 2 quarters · filed 2017-02-15 | -$281.99M derived: sum of 3 quarters · filed 2017-02-15 | -$510.36M derived: sum of 4 quarters · filed 2017-02-15 |
| 2014-12-31 | $21.43M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-15 | $59.34M derived: sum of 2 quarters · filed 2017-02-15 | -$169.03M derived: sum of 3 quarters · filed 2017-02-15 | -$548.81M 10-K · filed 2017-02-15 |
| 2014-09-30 | $37.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | -$190.47M derived: sum of 2 quarters · filed 2015-11-09 | -$570.25M 10-Q · filed 2015-11-09 | -$514.20M derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-06-30 | -$228.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | -$608.15M 10-Q · filed 2015-08-07 | -$552.11M derived: sum of 3 quarters · filed 2016-02-12 | -$554.61M derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-03-31 | -$379.78M 10-Q · filed 2015-05-08 | -$323.73M derived: sum of 2 quarters · filed 2016-02-12 | -$326.24M derived: sum of 3 quarters · filed 2016-02-12 | -$379.44M derived: sum of 4 quarters · filed 2016-02-12 |
| 2013-12-31 | $56.05M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-12 | $53.54M derived: sum of 2 quarters · filed 2016-02-12 | $335.00K derived: sum of 3 quarters · filed 2016-02-12 | -$130.50M 10-K · filed 2016-02-12 |
| 2013-09-30 | -$2.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | -$55.71M derived: sum of 2 quarters · filed 2014-11-06 | -$186.55M 10-Q · filed 2014-11-06 | |
| 2013-06-30 | -$53.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-08 | -$184.05M 10-Q · filed 2014-08-08 | ||
| 2013-03-31 | -$130.84M 10-Q · filed 2014-05-09 | |||
| 2012-12-31 | $3.37M 10-K · filed 2015-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |